CAR-T CDMOs — Ranked by Signal Score · 2026
CAR-T manufacturers on CDMO Signal: 31 listed. 6 are fully evidenced (all four Signal Score pillars and at least one ClinicalTrials.gov match). The highest Signal Scores in that fully evidenced set are Bristol Myers Squibb (CGT Mfg) (in-house manufacturer, Signal Score 87), Novartis (in-house manufacturer, Signal Score 85.4) and City of Hope (T Cell Manufacturing) (academic or national centre, Signal Score 84). Outside that set, higher Signal Scores on this list include Charles River Laboratories (Signal Score 86.3). A higher score there is not a fully evidenced record. Signal Score is computed from FDA inspection records, EMA EudraGMDP and MHRA GMP certificates, and ClinicalTrials.gov. CDMOs cannot pay to change it. Updated 2026-10-20. Methodology.
CAR-T CDMOs with the most regulatory evidence on file
CAR-T CDMOs manufacture engineered T-cell products, combining viral-vector transduction, T-cell activation and expansion, and rapid release testing — usually as autologous, per-patient batches on tight vein-to-vein timelines.
Choosing a CAR-T CDMO depends on autologous vs allogeneic experience, in-house vs sourced vector, closed-system processing, and chain-of-identity logistics, alongside a clean regulatory record. The rankings below score each CDMO on FDA inspections, GMP certification, clinical activity, and capacity.
FDA inspection outcomes across these CDMOs: 24 NAI (no action), 24 VAI (voluntary action), 0 OAI (official action). Leading inspection & GMP sites: United States (35), Austria (30), Denmark (23), Slovenia (13), Germany (12).
Last updated 2026-10-20. Sourced from FDA, EMA EudraGMDP, MHRA GMDP, and ClinicalTrials.gov.
Ranked by Signal Score (0–100). Fully evidenced marks a CDMO scored on all four pillars with at least one confirmed clinical program. Partly scored and profile-only CDMOs follow the scored rows. How we score
Showing contract manufacturers only.
| # | CDMO | Signal Score | Quality | FDA · GMP | Last FDA inspection | Capacity | Programs |
|---|---|---|---|---|---|---|---|
| 1 |
CR
Newbury Park, CA · Memphis, TN · Keele, UK · Rockville, MD
|
86.3 | 99.2 | 9 insp · 11 GMP | 2026-05-01 · NAI | Limited | — |
| 2 |
MN
Philadelphia, PA · Allendale, NJ · Munich, DE · Yokohama, JP
|
83.1 | 99.2 | 3 insp · 4 GMP | 2025-11-25 · NAI | Limited | — |
| 3 |
WB2
Shanghai, CN · Wuxi, CN
|
82.7 | 99.6 | 1 insp · 4 GMP | 2026-07-03 · VAI | — | — |
| 4 |
SC
Prague, Czech Republic
|
81.6 | 100.0 | 0 insp · 5 GMP | None on file | — | — |
| 5 |
NV
Morris Plains, NJ · Stein, CH
Fully evidenced
Also makes its own products
|
81.4 | 97.4 | 2 insp · 0 GMP | 2025-07-11 · VAI | Constrained | 284 programs |
| 6 |
CF
Les Ulis, FR
|
80.3 | 100.0 | 0 insp · 4 GMP | None on file | — | — |
| 7 |
AG
Longmont, CO · Milan, IT · Copenhagen, DK · Chiba, JP
Hiring · 38 open roles
Fully evidenced
|
79.9 | 99.8 | 4 insp · 27 GMP | 2026-05-29 · NAI | Available | 2 programs |
| 8 |
RC
|
79.3 | 96.8 | 1 insp · 1 GMP | 2025-01-21 · VAI | Available | — |
| 9 |
MB
|
73.0 | 100.0 | 0 insp · 2 GMP | None on file | — | 8 programs |
| 10 |
VE
Rockville, MD · Memphis, TN · Keele, United Kingdom
|
64.0 | — | — | None on file | — | — |
| 11 |
PBI
Pennington, NJ · Nanjing, CN
|
64.0 | — | — | None on file | — | — |
| 12 |
HG
|
63.0 | — | — | None on file | — | — |
| 13 |
OB
Hamilton, ON
|
61.5 | — | 0 insp · 2 GMP | None on file | — | — |
| 14 |
MS
Princeton, NJ
|
59.0 | — | — | None on file | — | — |
| 15 |
EB
|
59.0 | — | — | None on file | — | — |
| 16 |
EX
|
59.0 | — | — | None on file | — | — |
| 17 |
CZ
Cologne, Germany
|
59.0 | — | — | None on file | — | — |
| 18 |
AS
|
59.0 | — | — | None on file | — | — |
| 19 |
CTP
Melbourne, Australia
|
59.0 | — | — | None on file | — | — |
| 20 |
PO
|
58.7 | — | — | None on file | — | 6 programs |
| 21 |
TR
Kusatsu, Shiga Prefecture, Japan
|
57.9 | — | — | None on file | — | 8 programs |